Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Shanghai IASO Biotechnology

Main focus: Gene editing for the treatment of cancer

Company stage: Clinical

Diseases: T- and B-cell malignancies

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Shanghai and Nanjing, China

Website: http://www.iasobio.com/

Pipeline: http://www.iasobio.com/proline.php

Shanghai IASO Biotechnology develops next generation allogeneic CAR-T cell therapies and uses CRISPR to make the CAR-T cells fratricide-resistent. The company is currently developing multiple pre-clinical programmes using CRISPR, to treat T- and B-cell malignancies.

Tags

HashtagShanghai IASO Biotechnology Co., Ltd

Company: Shanghai IASO Biotechnology
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine